Skip to content
Life Sciences Seed Founded 2022

Signatur Biosciences

Developer of molecular diagnostic kits compatible with standard PCR equipment. These kits simplify complex disease diagnosis by condensing RNA signatures into single PCR assays. This platform transforms standard qPCR machines into precision diagnostic tools. The technology integrates into existing hospital infrastructure, enabling clinicians to deliver insights. Founded in 2022, headquartered in London, United…

📍 London, United Kingdom · Genomics

Funding snapshot

Last roundSeed
Amount$7M
Date25 May 2025
Total raised$8M
Team size19

About

Developer of molecular diagnostic kits compatible with standard PCR equipment. These kits simplify complex disease diagnosis by condensing RNA signatures into single PCR assays. This platform transforms standard qPCR machines into precision diagnostic tools. The technology integrates into existing hospital infrastructure, enabling clinicians to deliver insights. Founded in 2022, headquartered in London, United Kingdom. The company has raised $7.5M in funding at the seed stage. The company operates in the Genomics sector. Its business model centers on Oncology. Founded in 2022, headquartered in London, United Kingdom. The company has raised $7.5M at the Seed stage. Backed by investors including Y Combinator, Ukri, Gov, IBA, Riceberg Ventures.

Business model

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine > Oncology

Team background

College Wise > Imperial College London

Institutional investors

Y Combinator Ukri Gov IBA Riceberg Ventures

Latest coverage

No articles yet.

Raising like Signatur Biosciences?

Analyze your pitch deck before your next raise.

Analyze My Deck →